Bayer Aktiengesellschaft: Business Overview, Financials & Competitive Analysis
Bayer Aktiengesellschaft scores 6/10 on the AskCyborg Cyborg Score (Solid). Bayer represents a recovery play with turnaround potential driven by pharmaceutical innovation and operational restructuring, contingent on litigation containment and deleveraging progress. Bayer demonstrates strong fundamentals with a robust pharma pipeline and diversified revenue streams across healthcare and agriculture. However, persistent litigation risks, debt challenges, and recent profit pressures constrain.
What is Bayer Aktiengesellschaft's industry? Bayer Aktiengesellschaft (bayer.com) operates in Pharmaceuticals & Agriculture / Life Sciences Conglomerate. AskCyborg classifies Bayer Aktiengesellschaft under Pharmaceuticals & Agriculture / Life Sciences Conglomerate in its company registry.
Bayer is a German healthcare and agriculture conglomerate where healthcare provides close to half the company's sales including pharmaceutical drugs, vitamins, and consumer healthcare products, while its crop science ...
Cyborg Score thesis
Bayer represents a recovery play with turnaround potential driven by pharmaceutical innovation and operational restructuring,...
Read the full analyst-debate transcript →Get the Latest Bayer Aktiengesellschaft Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBayer Aktiengesellschaft Overview
Pro stress-test →Bayer is a German healthcare and agriculture conglomerate where healthcare provides close to half the company's sales including pharmaceutical drugs, vitamins, and consumer healthcare products, while its crop science business sells seeds, pesticides, herbicides, and fungicides. The firm expanded through its 2018 acquisition of Monsanto. The company has a current market capitalization of $47.7B.
Strategic Profile
Pro stress-test →Bayer's stock has recovered significantly, with BofA Securities raising its 12-month price target to €55 from €35 following greater confidence after a U.S. Supreme Court development related to glyphosate litigation. The company projects a return to profit growth from 2026 onwards driven by a robust pharmaceutical pipeline, crop science optimizations, and internal restructuring aimed at significant savings.
Competitive Landscape
Pro stress-test →Bayer competes with multinational pharmaceutical companies including Novartis. In pharmaceuticals, Bayer faces competition from Roche, Merck, and other major pharma firms. In crop science and agricultural inputs, competitors include Corteva Agriscience, BASF, and other specialty chemical companies. Bayer's diversified portfolio across pharmaceuticals, consumer health, and crop science provides competitive advantages in integrated life sciences solutions.
Industry Context
Bayer Aktiengesellschaft operates in Pharmaceuticals & Agriculture / Life Sciences Conglomerate.
Key facts
Founded: 1863 · Headquarters: Leverkusen, Germany · Employees: 102,000 · Revenue: $50.6B · Market cap: $47.7B